The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 54 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 142 of 263 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for AZN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 15 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.749) is normal, around the industry mean (-1.421). P/E Ratio (27.660) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 44 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 188 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 17 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.421). P/E Ratio (24.370) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
AZN | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 12 | 4 | |
SMR RATING 1..100 | 44 | 33 | |
PRICE GROWTH RATING 1..100 | 36 | 41 | |
P/E GROWTH RATING 1..100 | 54 | 12 | |
SEASONALITY SCORE 1..100 | 15 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (55) in the Pharmaceuticals Major industry is in the same range as AZN (65). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
NVS's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as AZN (12). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as AZN (44). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
AZN's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as NVS (41). This means that AZN’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (54). This means that NVS’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 42% | 1 day ago 46% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 41% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 55% |
| MACD ODDS (%) | 1 day ago 62% | N/A |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 51% |
| Advances ODDS (%) | 13 days ago 57% | 3 days ago 55% |
| Declines ODDS (%) | 6 days ago 45% | N/A |
| BollingerBands ODDS (%) | 1 day ago 43% | 1 day ago 43% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 51% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
AZN (@Pharmaceuticals: Major) experienced а +1.57% price change this week, while NVS (@Pharmaceuticals: Major) price change was +2.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +1.53%, and the average quarterly price growth was +5.98%.
AZN is expected to report earnings on Feb 11, 2027.
NVS is expected to report earnings on Feb 03, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -1.39% | ||
| BIIB - AZN | 48% Loosely correlated | -0.64% | ||
| GILD - AZN | 39% Loosely correlated | +0.92% | ||
| GSK - AZN | 28% Poorly correlated | -0.60% | ||
| MRK - AZN | 26% Poorly correlated | -0.48% | ||
| NVS - AZN | 25% Poorly correlated | -0.26% | ||
More | ||||
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.